308367-90-0 Usage
Description
[2-(6-Amino-9H-purin-9-yl)-1-Methylethoxy]Methyl]-4-Morpholinylphosphinic Acid is a chemical compound that serves as an intermediate in the synthesis of Tenofovir Phosphate (T018510), which is a metabolite of Tenofovir (T018500). [2-(6-AMino-9H-purin-9-yl)-1-Methylethoxy]Methyl]-4-Morpholinylphosphinic Acid plays a crucial role in the development of pharmaceuticals, particularly those targeting viral infections.
Uses
Used in Pharmaceutical Industry:
[2-(6-Amino-9H-purin-9-yl)-1-Methylethoxy]Methyl]-4-Morpholinylphosphinic Acid is used as an intermediate in the synthesis of Tenofovir Phosphate (T018510) for its antiviral properties. Tenofovir Phosphate is a prodrug that is converted to its active form, Tenofovir, in the body. It is particularly effective against retroviruses, such as HIV and hepatitis B virus, making it a valuable component in the fight against these viral infections.
Additionally, the compound may have potential applications in other areas of pharmaceutical research, such as the development of new drugs or therapies for various diseases. However, further research and development would be required to explore these possibilities.
Check Digit Verification of cas no
The CAS Registry Mumber 308367-90-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,0,8,3,6 and 7 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 308367-90:
(8*3)+(7*0)+(6*8)+(5*3)+(4*6)+(3*7)+(2*9)+(1*0)=150
150 % 10 = 0
So 308367-90-0 is a valid CAS Registry Number.
308367-90-0Relevant articles and documents
Inhibition of HIV-1 replication in macrophages by red blood cell-mediated delivery of a heterodinucleotide of lamivudine and tenofovir
Franchetti,Cappellacci,Petrelli,Vita,Grifantini,Rossi,Pierige,Serafini,Magnani,Balestra,Perno
, p. 953 - 957 (2007)
Homo- and heterodimers of nucleoside/nucleotide analogues as reverse transcriptase inhibitors are effective on HIV-1-infected human monocyte-derived macrophages (M/M) compared to the single drugs or their combination. Since the combined treatment of lamivudine (3TC) and tenofovir ((R)PMPA) has an antiretroviral efficacy and a synergic effect respect to separate drugs, the heterodinucleotide 3TCpPMPA was synthesized. A single administration of the dimer as free drug or 3TCpPMPA-loaded RBC selectively targeted to M/M was able to almost completely protect macrophages from "de novo" infection. Copyright Taylor & Francis Group, LLC.
